A commentary notes that although liraglutide was effective at reducing the incidence of diabetes and in reversing prediabetes to normoglycaemia, this might not be the most cost-effective pathway. It suggests that lifestyle modification, which is much less expensive than is liraglutide, improves not only the risk for developing diabetes but also other components of metabolic syndrome such as hypertension and hyperlipidaemia. It adds that a direct comparison of these two interventions is lacking, and whether liraglutide is more effective in the longer term or whether other GLP-1 analogues are more effective than lifestyle modification alone also remains to be seen.